Cat. #161766
TOV-112D cell line
Cat. #: 161766
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from solid tumors of ovarian cancer patient
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Provencher et al. 2000. In Vitro Cell.Dev.Biol.-Animal (36): 357361. PMID:10949995
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: TOV-112D cell line
- Alternate name: TOV-112D
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from solid tumors of ovarian cancer patient
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 5; Pre-treatment
- Morphology: Able to form compact spheroids
- Crispr: No
- Receptors of note: No
- Description: Spontaneous immportilized epithelial ovarian cancer cell line derived from a patient never exposed to chemotherapy or radiation therapy. Cell line retains cahracteristics of the original epithelial ovarian cancers from which it was derived.
References
- Raspaglio et al. 2023. Cancers (Basel). 18
- 15(8):2361. PMID: 37190289 Yee et al. 2022. Front Bioeng Biotechnol. 10
- 10:836984. PMID: 35223797 Brodeur et al. 2021. Sci Rep. 14
- 11(1):18183. PMID: 34521878 Buttarelli et al. 2022. J Exp Clin Cancer Res. 4
- 41(1):50. PMID: 35120576
